Schizophrenia is a mental disorder that affects over 24 million people worldwide according to the World Health Organization and has a significant economic impact on society in terms of healthcare and indirect costs.  There is currently no cure for schizophrenia, but there are several antipsychotics on the market that treat the symptoms.  The first atypical antipsychotic developed for the treatment of schizophrenia, clozapine, was approved by the FDA over 20 years ago and while it remains one of the most effective drugs, it is prescribed sparingly due to its potentially severe side effects.  Several alternative antipsychotics with fewer side effects have been developed, but none have as high of a therapeutic effect as clozapine.  The goal of this project is to synthesize derivatives of clozapine, screen them against key schizophrenia receptors for biological activity and ultimately perform PET imaging studies with the most promising compounds to observe distribution in the brain.

Development and PET imaging of atypical antipsychotics for the treatment of schizophrenia

248th National Meeting (2014)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.